




CAR-T Congress USA

Maximising the Potential of CAR-T Therapy

21st-22nd March 2018 | Hilton Boston Dedham Hotel | Boston, MA

With Commercialization Day on 20th March (separately bookable)

Discover the potential of CAR-T

in solid
tumors with
break-through
research

Hear the novel protocols

from leaders
in the industry
working to shape
the future of
immuno-oncology

Collaborate and partner

with leading
figures &
institutions
with a dedicated
commercialization
day

Discuss strategies to improve patient access

and improve
the commercial
viability of CAR-T
therapies

40+
SPEAKERS


100+
ATTENDEES

50:50
RATIO
of Academics
to Industry

20+
1-TO-1
Meetings Available
per Attendee

1
DEDICATED
Poster
Session

Presenting Institutions:




Presented by:

**Kisaco
Research**

Register: www.car-tcongress.com • +44 (0)20 3696 2920

TIMELINE OF CAR-T



WHO YOU WILL MEET

THIS 2 DAY PROGRAM HAS BEEN DEVELOPED TO ADDRESS THE KEY AREAS OF DISCUSSION FOR:

- **ACADEMICS:**

Professors and R&D experts from world-leading institutions and Cancer centers, working in Cellular Therapeutics, Oncology, Immunology and Immuno-oncology

- **PHYSICIANS:**

Oncologists, Immunologists and Haematologists

- **PHARMACEUTICAL:**

CEOs, CSOs, Senior Management, Principal Scientists, Heads of CAR-T, Cell Therapy, Process Development, Non-Clinical Safety, Research and Development, Business Development and Strategic Teams

- **BIOTECHS:**

Founders of emerging companies and start-ups, CSOs, early to clinical stage cell therapy companies globally

- **SERVICE PROVIDERS:**

Consultants, CMOs, CROs

GET INVOLVED

POSTER PRESENTATIONS

Showcase your work to the cell therapy community with our dedicated poster sessions. Get involved and get your research noticed in the dedicated poster area. Poster presentations will run during breaks and at scheduled times alongside sessions.

Submit your poster on our website

Deadline: 2nd March 2018

EMERGING COMPANY SHOWCASE

Are you an academic, early stage start-up or emerging company looking to commercialize your latest innovation and technology? You're invited to present the commercial opportunities of your development to investors looking to hear about the next big development.

Apply on our website

MEETING MOJO

Collaboration and building relationships is at the core of the CAR-T Congress. In addition to the scheduled networking breaks, our 'MEETING MOJO' platform enables you to create a bespoke meeting schedule, ensuring you connect with those with similar interests.

REGISTER TODAY

KEY SESSIONS:

- **Targeting, Control & Safety:** The development of safety switches and antigen discovery for solid tumors
- **Scalability & Automation:** Novel protocols to scale up production whilst ensuring quality is not compromised
- **Alternative CAR Constructs:** CAR-NK, CAR-Tregs, gamma delta CAR-T and the use of CARs on alternative cell types
- **Commercialisation, Regulation & Patient Access:** How to navigate the regulatory processes to create commercially viable treatments

INTERESTED IN SPONSORSHIP OPPORTUNITIES?

Far from the typical 'meet-and-greet' exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list. With our extensive marketing experience and strategy, your partnership with the conference will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts.

Sponsorship opportunities include exhibition, presentations, branding and an innovation showcase. Get in touch to find out ways to get involved.

Contact **Ben Edwards** to find out more about each package by emailing events@kisacoresearch.com or by calling +44 (0)20 3696 2920

COMMERCIALIZATION DAY



Take advantage of a dedicated day for collaboration and partnering. Networking opportunities will be enhanced with 1-to-1 meetings between academia, start-ups, spin-offs and those looking to invest and commercialize on emerging technologies. Hear first-hand experience of the investment process and most importantly meet the decision makers to discuss partnerships and opportunities to work together in the future.

10:00 – 10:15 **Introductory talk - The CAR-T industry landscape**

An overview into recent developments & areas of growth

10:15 – 11:00 **DISCUSSION: CAR-T achievements & the routes to commercialization**

- What challenges need to be overcome before CAR-T can be a commercially viable therapy?
- How to identify emerging companies from pre-clinical data?
- Obstacles facing emerging companies

Panellists:

Karim Helmy, Vice President, **Venrock**

James Noble, CEO, **Adaptimmune**

11:00 -11:40 **NETWORKING BREAK**

11:00-11:20 – meeting slot 1

11:20-11:40 – meeting slot 2

11:40 – 12:20 **WORKSHOP**

- Intellectual Property: a CAR-T cell entrepreneur's experience
- Challenges of CAR-T cell commercialization

Ronald Dudek, **Living Pharma**

12:20 – 13:50 **LUNCH & MEETING MOJO NETWORKING BREAK**

12:50-13:10 – meeting slot 1

13:10-13:30 – meeting slot 2

13:50 – 14:20 **CAR-T Cell Therapy for Brain Tumors: Logistical Challenges and Opportunities**

Sadik H. Kassim, Ph.D., Vice President, Process and Analytical Development, **Mustang Bio, Inc.**

14:20 – 15:10 **DISCUSSION: From bench to bedside: translating technologies from concept to reality**

- Collaborative approaches to research
- Identifying emerging technologies
- Defining objectives & strategies for commercialization
- Bridging the gap between industry & academia

Panellists:

Gary Sclar, **Dana Farber Innovations**

Michael Poisel, **Penn Center for Innovation**

15:10 – 16:10 **MEETING MOJO NETWORKING SESSION**

15:10-15:30 – meeting slot 1

15:30-15:50 – meeting slot 2

15:50-16:10 – meeting slot 3

16:00 **CHAIR'S CLOSING REMARKS**

AGENDA DAY 1

TARGETING, CONTROL & SCALABILITY



8:00 - 8:25

REGISTRATION

8:25 - 8:30

CHAIR'S OPENING REMARKS

Matthew Hewitt, Principal Scientist/Director, Tumor Microenvironment, **Bellicum Pharmaceuticals**

8:30 - 9:00

KEYNOTE: VERY RAPID MANUFACTURING OF GENETICALLY MODIFIED T CELLS FOR CANCER: HELPING TO SOLVE ISSUES OF COST AND SCALE UP

Laurence Cooper, Chief Executive Officer, **Ziopharm**

9:00-9:30

DISCUSSION: The Race To Solid Tumor Targeting

- Will TCRs or bi-specific T-cell engagers overtake CAR-T?
- Can CAR-T have the same success in solid tumors as in hematological tumors?

Panellists:

Jeff Till, Head of New Technologies, External Innovation, Biopharma, Global Research and Development, **EMD Serono, Inc.**

Neil Sheppard, Head External Co-operations & Early Development Leader, **GSK**

Robert Hofmeister, Chief Scientific Officer, **TCR2**

9:30-10:00

OVERCOMING THE CHALLENGES & COMPLEXITIES OF THE PERSONALIZED MEDICINE SUPPLY CHAIN

Scott Ohanesian, Senior VP, Commercial Operations, **QuickSTAT**

10:00 - 10:40

Networking break

10:00-10:20 - Meeting slot 1

10:20-10:40 - Meeting slot 2

10:40 - 11:10

SESSION: SCALABILITY, MANUFACTURING & ALLOGENEIC PRODUCTS: MICROFLUIDIC TOOLS TO STREAMLINE CELL THERAPY PROCESSING

Jason Fiering, Distinguished Technical Staff, **Draper Lab**

11:10 - 11:40

ENGINEERING PLURIPOTENT CELLS FOR OFF-THE-SHELF CANCER IMMUNOTHERAPY

Bob Valamehr, PhD MBA, Vice President, Cancer Immunotherapy, **Fate Therapeutics Inc**

11:40 - 12:10

UCART "OFF-THE-SHELF" ALLOGENEIC PRODUCTS

David Sourdivo, Vice President of Corporate Development, **Collectis**

12:10 -13:40

LUNCH & NETWORKING BREAK

13:40 - 14:10

SESSION: SOLID TUMOR TARGETING, DELIVERY & CONTROL: DEVELOPING MOLECULAR CONTROL SWITCHES FOR CAR-T IN TARGETING SOLID TUMORS

Matthew Hewitt, Principal Scientist/Director, Tumor Microenvironment, **Bellicum Pharmaceuticals**

14:10-14:40

TARGETING MOLECULES FOR SOLID TUMORS

Dr Bijal Shah, MD Medical Oncology, **Moffitt Cancer Center**

AGENDA DAY 1 Continued

TARGETING, CONTROL & SCALABILITY



14:40-15:10 **IMPACT SOLID & HEMATOLOGIC CANCERS WITH SAME CAR-T: CYAD-01 AN INTEGRATED CLINICAL DEVELOPMENT**

Peggy Sotiropoulou, R&D Manager, [Celyad](#)

15:10 – 15:50 **NETWORKING BREAK & POSTER PRESENTATION SESSION**

15:10-15:30 - Meeting slot 1

15:30-15:50 - Meeting slot 2

15:50-16:20 **PREDICTING TUMOR-SPECIFIC NEOANTIGENS FROM SEQUENCE DATA –DRIVING PERFORMANCE WITH MACHINE LEARNING**

Roman Yelensky, Chief Technology Officer, [Gritstone Oncology](#)

16:20 – 16:50 **NOVEL APPROACHES TO GENE ENGINEERING: THE POTENTIAL OF CRISPR TO INCREASE EFFICACY OF CELL THERAPIES**

Yangbing Zhao, Perelman School of Medicine, [University of Pennsylvania](#)

16:50 -17:20 **WORKSHOP: MASTERING THE COMPLEXITY OF CELL THERAPY MANUFACTURING WITH THE CLINIMACS PRODIGY**

- Miltenyi Biotec's cell therapy offering and experience with commercial scale CAR-T manufacturing
- A live demonstration of our 'T Cell Transduction' process on the CliniMACS Prodigy, a functionally closed device for end-to-end automation of CAR-T Cell manufacturing

Meghan Monzon, National Director Biopharma Partnerships, [Miltenyi Biotec](#)

Daniel Weinstein, Cell and Gene Therapy Area Manager, [Miltenyi Biotec](#)

17:20 **CLOSING REMARKS**

17:30-18:30 **BOSTON CAR-T PARTY**

NETWORKING DRINKS

Hosted by **MILTENYI BIOTEC**

AGENDA DAY 2

TOXICITY, COMMERCIALIZATION, REGULATION & ALTERNATIVE CARs



8:00-8:25	REGISTRATION
8:25-8:30	CHAIR'S OPENING REMARKS
8:30-9:00	DEVELOPMENT OF ALLOGENEIC & AUTOLOGOUS BCMA-SPECIFIC CAR-T THERAPIES Devon Shedlock, VP of Pre-clinical Development, Poseida
9:00-9:30	PANEL: THE OBSTACLES TO PATIENT ACCESS: WHAT CONSIDERATIONS ARE NEEDED TO OVERCOME THE CHALLENGES OF EXPANDING CAR-T CELL THERAPY TO A GLOBAL PATIENT POPULATION? Panellists: Biren Mistry, Associate Director, Celgene Gary C. Du Moulin, Ph.D., Adjunct Associate Professor of Regulatory Affairs, Massachusetts College of Pharmacy and Health Sciences University Julie Smolich, MBA, Vice President of Product Management, Be The Match BioTherapies
9:30-10:00	STRATEGIC CONSIDERATIONS FOR THE DEVELOPMENT OF CAR-T CELL THERAPY Biren Mistry, Associate Director, Celgene
10:00-10:40	NETWORKING BREAK <i>10:00-10:20 - Meeting slot 1</i> <i>10:20-10:40 - Meeting slot 2</i>
10:40-11:10	ADOPTIVE $\gamma\delta$ T CELL & DRUG RESISTANT IMMUNOTHERAPY AS A STRATEGY FOR ELIMINATION OF RESIDUAL MALIGNANCY Lawrence Lamb, Co-Founder, Incytus
11:10-11:40	A NOVEL CLASS OF T CELL THERAPIES FOR SOLID TUMORS THAT UTILIZE THE FULL SIGNALLING POWER OF COMPLETE T CELL RECEPTORS (TCR) Alfonso Quintas-Cardama, Chief Medical Officer, TCR2
11:40-12:10	OBSTACLES TO PATIENT ACCESS: LESSONS LEARNED FROM A CARTILAGE REPAIR CELL THERAPY Gary C. Du Moulin, Ph.D., M.P.H., Adjunct Associate Professor of Regulatory Affairs, Massachusetts College of Pharmacy & Health Sciences University
12:10-13:30	LUNCH & NETWORKING BREAK
13:30 – 14:00	ROUNDTABLE SESSION • Can technology keep up with the pace of discovery? How can we improve manufacturing? • Viral Vectors vs non-viral vectors • Will CAR-T be overtaken by alternative CARs? • Allogeneic vs Autologous: can off-the-shelf products compete?
14:00-14:30	CAR MACROPHAGES: NEXT GENERATION IMMUNOTHERAPY Michael Klichinsky, Co-Founder, CARMA Therapeutics

AGENDA DAY 2 Continued

TOXICITY, COMMERCIALIZATION, REGULATION & ALTERNATIVE CARs

14:30-15:10 **NETWORKING BREAK**

14:30 – 14:50 - Meeting slot 1

14:50-15:10 - Meeting slot 2

15:10-15:40 **CAR-T REGS: CARs FOR AUTOIMMUNE DISEASE**

Stephane Boissel, CEO, [TxCell, France](#)

15:40-16:10 **BROADLY-SPECIFIC CYTOTOXIC T CELLS TARGETING MULTIPLE HIV ANTIGENS ARE EXPANDED FROM HIV & PATIENTS: IMPLICATIONS FOR IMMUNOTHERAPY**

Russell Cruz, Assistant Professor, [Children's National Medical Center](#)

16:10 **CHAIR'S CLOSING REMARKS**

EXPERTISE **PARTNER**



Miltenyi Biotec

Miltenyi Biotec's mission is to improve scientific understanding and medical progress. By developing innovative products that address the processes that are necessary for the study of immuno-oncology we help researchers advance science in these key areas as well as help clinicians to make the concept of cellular therapy a reality. www.miltenyibiotec.com

THOUGHT LEADERSHIP **PARTNERS**



QuickSTAT

For 35 years, QuickSTAT has managed clinical trial logistics in more than 150 countries worldwide. With innovative solutions that offer complete end-to-end transportation services, your time and temperature-sensitive clinical research specimens, investigational drugs, and biologics are handled with unmatched attention, reliability and care. www.quickstat.aero



BE THE MATCH BIOTHERAPIES

Be The Match BioTherapies partners with organizations pursuing life-saving cellular therapies in every stage of development – from discovery through commercialization. Built on the foundation established over the last 30 years by the National Marrow Donor Program®/Be The Match®, we have unparalleled experience managing cellular therapies.

Our cell therapy supply chain delivery for autologous or allogeneic therapies is enabled by high-touch, personalized case management and a robust, customizable technology platform, MatchSource. Our experience in cell sourcing and collection allows us to provide cells consented for research, clinical or commercial use. Researchers have access to clinical trial services through our research program, the CIBMTR. And, we have the infrastructure in place to collect, store and analyze patient samples post-cell or gene therapy treatment at the time points required by regulatory authorities.

www.bethematchbiotherapies.com



BioSpherix

BioSpherix will be exhibiting the Xvivo System, the only cytocentric barrier isolator optimized for cells. Economical alternative to cleanrooms for cGMP compliant production of cells for clinical use. Stop by BioSpherix booth to learn more about the only total quality platform for cells!

Total quality recognizes that for best cell potency, cells need full-time optimization of all critical cell process parameters. Total quality recognizes that all typical negative side effects of machines on cells (particles, heat, vibration, etc.) must be neutralized and those machines must be protected from dust, aerosols, and corrosion. Total quality recognizes that each entire cell production line (all manual and automated steps) must be protected from microbial contamination. Total quality recognizes that all personnel must be fully protected from cells harboring virus, vectors, prion, and other pathogens. Total quality recognizes that scaling up and out must be efficient and cost efficient.

www.BioSpherix.com

EVENT PARTNERS



TrakCel

TrakCel is the market leading designer, developer and deliverer of integrated technologies specifically created in 2012 to manage the international autologous and allogeneic cell, gene and immunotherapy supply chain. TrakCel's software platform has been developed in collaboration with, and increasingly adopted by leading companies in the cell, gene and immunotherapy industries. TrakCel's solutions deliver real-time control over the entire therapeutic supply chain, from sample collection through manufacturing to treatment delivery. The TrakCel platform accelerates global scale-up and scale-out of cell and gene therapy products, increasing efficiency and decreasing complexity, while maintaining needle-to-needle compliance and traceability.

TrakCel is headquartered in Cardiff, Wales, UK with US offices in California and New Jersey. It aims to employ over 100 people by end of 2019, following a number of senior appointments in 2016 and 2017.

www.trakcel.com



PRA Health Sciences

PRA Health Sciences delivers innovative drug development solutions that improve patients' lives. Our people are passionate about clinical research, working tirelessly to provide quality results for clients. We offer exceptional experience across all phases, therapeutic areas and a broad spectrum of solutions, ranging from full-service clinical development to our pioneering embedded model.

With 15,000+ employees covering 85+ countries, we bolster an impressive global presence with keen local insights. Our project teams harness their understanding of local regulations, standards of care and cultural customs to effectively align our approaches with each study's unique goals.

At PRA, we love what we do because we are making a difference in the lives of patients and their family members worldwide. Over the years, we have contributed to the development of numerous drugs now available to countless patients. From our scientific and medical experts to therapeutically aligned project managers and monitors, we provide the commitment and expertise needed for today's complex studies.

www.BioSpherix.com



Dana Farber

Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

www.dana-farber.org



CountStar®

Introducing Countstar® Cell Analysis Systems, a line of instruments with an innovative combination of advanced technologies. Countstar® brings together the functionality of digital microscopes, cytometers and automated cell counters into its intuitively designed systems. By combining bright-field and fluorescent imaging with classical dye-exclusion technologies, extensive data on cell morphology, viability, and concentration is generated in real time. Countstar® Systems go further by generating high-resolution images, the essential basis for sophisticated data analysis. With more than 1,000 analyzers installed worldwide, Countstar® analyzers are proven to be valuable tools in research, process development, and validated production environments.

The Countstar® brand was inspired by the endless possibilities a person experiences when counting stars in the night sky. With this approach, Countstar® explores the limits of technology. Countstar® was founded by ALIT Life Sciences, an emerging manufacturer of innovative equipment and consumables for the biological research community. Headquartered in the high-tech district of Shanghai, ALIT Life Sciences develops and produces the analytical equipment of the future.



World Courier

World Courier is a global specialty logistics company that designs world-class logistics and supply chain programs in complete alignment with our customers' business goals. Pharmaceutical companies rely on us because they value the peace of mind that comes with our unsurpassed knowledge, global reach and flawless supply chain execution. Each trusted partnership we form with a customer deeply rooted in our shared vision of improving global health. With 2,500+ associates in more than 140 offices across the globe, we offer solutions that instill confidence in the on-time, on-temperature delivery of critical products. When trust is absolutely essential, there's only one choice: World Courier.

www.worldcourier.com

LOCATION AND PRICING

Venue: Hilton Boston Dedham Hotel • 25 Allied Drive • Dedham, MA 0206



PRICING INFORMATION

PASS TYPE	EARLY BIRD 1 Before 12th January 2018	EARLY BIRD 2 Before 9th February 2018	STANDARD PRICING
BIOPHARMA/BIOTECH			
2 day conference	\$1,299	\$1,499	\$1,699
2 day conference & commercialization day	\$1,998	\$2,198	\$2,398
VENDORS			
2 day conference	\$1,499	\$1,699	\$1,899
2 day conference & commercialization day	\$2,198	\$2,398	\$2,598
ACADEMIC / NON PROFIT / EMERGING			
2 day conference	\$799	\$799	\$799
2 day conference & commercialization day	\$999	\$999	\$999
COMMERCIALIZATION DAY ONLY	\$999	\$1,199	\$1,399

BOOK A TEAM TO SAVE MORE!

Industry Rates Only: Team discounts cannot be combined with any other discount or offer

Book a Team of 3+

Save an Additional 10% Off

Book a Team of 5+

Save an Additional 15% Off

Payment Terms:

- Please note that a \$79 processing fee will apply to any invoices requested.
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- No discount offers can be combined with any other offer
- Please view our Cancellation Policy
- QUESTIONS? Please email events@kisacoresearch.com